| Project/Area Number |
25640085
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Tumor therapeutics
|
|---|
| Research Institution | Tokyo University of Agriculture and Technology (2015)
Tohoku University (2013-2014) |
|---|
Principal Investigator |
ASANO Ryutaro 東京農工大学, 工学(系)研究科(研究院), 准教授 (80323103)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
UMETSU Mitsuo 東北大学, 大学院工学研究科, 教授 (70333846)
|
|---|
| Project Period (FY) |
2013-04-01 – 2016-03-31
|
| Project Status |
Completed (Fiscal Year 2015)
|
| Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2013: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
|
|---|
| Keywords | 癌 / 蛋白質 / バイオテクノロジー / 生物・生体工学 / 四重特異性四価抗体 |
|---|
| Outline of Final Research Achievements |
Although small bispecific antibodies are attractive molecules, their decreases in binding valency and in vivo half-life are left as a problem. Multimerization of small antibodies is one strategy to solve these drawbacks. In this study using four kinds of antibody fragments, we tried to develop small tetraspecific and tetravalent cancer therapeutic antibodies to regulate multimeric structure and to enhance therapeutic efficacy. We couldn’t obtain the functional molecules in bacterial expression system; however, we successfully prepared tetraspecific and tetravalent antibodies with high therapeutic effects in mammalian expression system. Further, our results showed that Fc fusion to facilitate their purification causes decreases in their cytotoxic effects.
|
